CoChat
Sign Up
Cited by 49Diabetes Treatment and ManagementDrug-Induced Ocular ToxicityPharmacology and Obesity Treatment

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Glucagon‐like peptide 1 ( GLP1 ) receptor agonists and risk for ischemic optic neuropathy: A meta‐analysis of randomised controlled trials

Open access
Silverii, Giovanni Antonio, Pala, Laura, Cresci, Barbara, Mannucci, Edoardo·2025·Diabetes, Obesity and Metabolism
DOI 10.1111/dom.16076PMC PMC11701179
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUNDGlucagon-like peptide-1 receptor agonists (GLP-1 RA) are an established treatment for type 2 diabetes; due to their weight-reducing effect, some of the molecules of the class are increasingly used as a treatment for obesity. 1 The use of GLP-1 RA is associated with a reduction of major cardiovascular events, 2 with possible improvements of heart failure, 3,4 and renal function.5 An increased risk for worsening pre-existing diabetic retinopathy was also observed in a large trial with semaglutide, 6 but it may be the consequence of a sudden and wide reduction of hyperglycaemia.7 Recently, a retrospective observational study highlighted the possibility of an association of semaglutide treatment with a more than four-fold increase in risk for nonarteritic anterior ischemic optic neuropathy (NAION), but the results could be affected by selection bias, as the study was performed in a sample referring to a specialist facility.8 NAION, a condition potentially leading to blindness, is relatively rare in the general population (2-10/100 000 cases/year), 9,10 but more frequent in patients with obesity, diabetes and possibly obstructive sleep apnoea.10,11 Because GLP-1 receptors have been detected in neuronal cells in the human eye, 12 a possible effect of GLP1-RA on optic neuropathy is not implausible.However, a retrospective study, even when well-designed, cannot provide any demonstration of causal relationships, because the possibility of confounding factors cannot be entirely ruled out.In case of suggestions of safety issues detected in observational studies, the retrieval of specific data from randomised trial can therefore add relevant information.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.16076

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 7

  1. 10.1038/s41591‐023‐02538‐7 · DOI
  2. 10.1007/s00417‐023‐06236‐5 · DOI
  3. 10.1016/S0002‐9394(14)70999‐7 · DOI · Paper page
  4. 10.1097/WNO.0000000000002102 · DOI · Paper page
  5. 10.1007/s00417‐023‐06103‐3 · DOI
  6. 10.1111/dom.15226 · DOI · Paper page
  7. 10.1001/jamaophthalmol.2023.2289 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Silverii, G. A., Pala, L., Cresci, B., & Mannucci, E.
Affiliations
  • University of Florence (IT)
  • Azienda Ospedaliero-Universitaria Careggi (IT)
Corresponding author
Silverii, Giovanni Antonio
ORCID
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2024-11-20
Volume
27
Issue
2
Pages
1005-1009
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
DOI
10.1111/dom.16076
PMC
PMC11701179
OpenAlex
W4404547014
Cited by
49
References
9
Citations by year
2026: 27 · 2025: 22
FWCI
16.14
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Obesity and Metabolism (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Florence Research (University of Florence) (submittedVersion, cc-by-nc)
Funders
Università degli Studi di Firenze
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
GLP-1 receptor agonists, ischemic optic neuropathy, nonarteritic anterior ischemic optic neuropathy, semaglutide, drug safety, type 2 diabetes, obesity, adverse drug reactions, diabetic retinopathy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review